Growth Metrics

NeuroPace (NPCE) Asset Writedowns and Impairment (2020 - 2026)

NeuroPace has reported Asset Writedowns and Impairment over the past 7 years, most recently at $76000.0 for Q1 2026.

  • For Q1 2026, Asset Writedowns and Impairment rose 72.73% year-over-year to $76000.0; the TTM value through Mar 2026 reached $232000.0, down 6.45%, while the annual FY2025 figure was $200000.0, 20.32% down from the prior year.
  • Asset Writedowns and Impairment for Q1 2026 was $76000.0 at NeuroPace, up from $60000.0 in the prior quarter.
  • Over five years, Asset Writedowns and Impairment peaked at $107000.0 in Q3 2024 and troughed at -$4000.0 in Q4 2022.
  • A 5-year average of $54294.1 and a median of $49000.0 in 2025 define the central range for Asset Writedowns and Impairment.
  • Biggest five-year swings in Asset Writedowns and Impairment: plummeted 107.02% in 2022 and later soared 1700.0% in 2023.
  • Year by year, Asset Writedowns and Impairment stood at -$4000.0 in 2022, then soared by 1700.0% to $64000.0 in 2023, then decreased by 14.06% to $55000.0 in 2024, then increased by 9.09% to $60000.0 in 2025, then increased by 26.67% to $76000.0 in 2026.
  • Business Quant data shows Asset Writedowns and Impairment for NPCE at $76000.0 in Q1 2026, $60000.0 in Q4 2025, and $47000.0 in Q3 2025.